down arrow

Avalo Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05338F3064
USD
17.95
2.08 (13.11%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

16.6318.80

52 Week

3.3919.40
Valuation
Technical
Day's Volume

CASH

381.09 k

Shareholding (Mar 2025)

FII

1.14%

Held by 9 FIIs

DII

82.19%

Held by 4 DIIs

Promoter

13.91%

How big is Avalo Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Avalo Therapeutics, Inc. has a market capitalization of 48.40 million, with net sales of 0.44 million and a net profit of 73.01 million over the latest four quarters. The company reported shareholder's funds of 133.03 million and total assets of 150.73 million as of Dec 24.

Market Cap: As of Jun 18, Avalo Therapeutics, Inc. has a market capitalization of 48.40 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Avalo Therapeutics, Inc. reported net sales of 0.44 million and a net profit of 73.01 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 133.03 million and total assets of 150.73 million.

Read More

What does Avalo Therapeutics, Inc. do?

22-Jun-2025

Avalo Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for pediatric and orphan diseases. As of March 2025, it has a market cap of $48.40 million and reported a net profit loss of $13 million.

Overview: <BR>Avalo Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for pediatric and orphan diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 48.40 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -37.56% <BR>Price to Book: 0.39<BR><BR>Contact Details: <BR>Address: 540 Gaither Rd Ste 400, ROCKVILLE MD: 20850-6713 <BR>Tel: 1 410 5228707 <BR>Fax: 1 302 6365454 <BR>Website: http://www.cerecor.com

Read More

Who are in the management team of Avalo Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Avalo Therapeutics, Inc.'s management team includes Dr. Sol Barer (Chairman), Mr. Michael Cola (CEO and Director), and Directors Dr. Suzanne Bruhn, Mr. Joseph Miller, Mr. Steven Boyd, Mr. Phil Gutry, and Dr. Gilla Kaplan, with Boyd, Gutry, and Kaplan serving as Independent Directors.

As of March 2022, the management team of Avalo Therapeutics, Inc. includes Dr. Sol Barer as the Chairman of the Board, Mr. Michael Cola as the Chief Executive Officer and Director, and Dr. Suzanne Bruhn, Mr. Joseph Miller, Mr. Steven Boyd, Mr. Phil Gutry, and Dr. Gilla Kaplan as Directors, with the latter three serving as Independent Directors.

Read More

Is Avalo Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Avalo Therapeutics, Inc. is considered overvalued with key ratios indicating insufficient value generation, despite a strong year-to-date stock performance, and a concerning long-term return of -99.85%.

As of 8 July 2024, Avalo Therapeutics, Inc. has moved from a risky valuation grade to one that does not qualify. Given the current metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 0.36, an EV to EBIT of 1.55, and an EV to EBITDA of 1.56, which suggest that the company is not generating sufficient value relative to its market price.<BR><BR>In comparison to peers, Avalo's valuation ratios are significantly lower, with 180 Life Sciences Corp. showing an EV to EBITDA of -61.84 and ABVC BioPharma, Inc. at -23.18, indicating that Avalo is not alone in facing valuation challenges within its sector. Despite recent stock performance showing a 59.89% year-to-date return compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a staggering -99.85% return over the past five years.

Read More

Is Avalo Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Avalo Therapeutics, Inc. shows a strong bullish trend supported by positive technical indicators, significantly outperforming the S&P 500 in the short term, despite longer-term declines.

As of 3 September 2025, the technical trend for Avalo Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The monthly MACD and KST are mildly bullish, indicating some strength in the longer term. <BR><BR>In terms of performance, Avalo has outperformed the S&P 500 significantly over the past week (9.19% vs. 1.05%) and month (31.13% vs. 2.33%), while the year-to-date return of 59.89% also surpasses the S&P's 12.22%. However, the longer-term returns over 3 years and 5 years show substantial declines compared to the S&P 500. Overall, the current technical indicators suggest a strong bullish sentiment in the short to medium term.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 150 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.06

stock-summary
Return on Equity

-53.42%

stock-summary
Price to Book

1.44

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-21 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
70.06%
0%
70.06%
6 Months
307.95%
0%
307.95%
1 Year
80.22%
0%
80.22%
2 Years
14.89%
0%
14.89%
3 Years
214.91%
0%
214.91%
4 Years
-99.65%
0%
-99.65%
5 Years
-99.76%
0%
-99.76%

Avalo Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Avalo Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Avalo Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The monthly MACD and KST are mildly bullish, indicating some strength in the longer term. In terms of performance, Avalo has outperformed the S&P 500 significantly over the past week (9.19% vs. 1.05%) and month (31.13% vs. 2.33%), while the year-to-date return of 59.89% also surpasses the S&P's 12.22%. However, the longer-term returns over 3 years and 5 years show substantial declines compared to the S&P 500. Overall, the current technical indicators suggest a strong bullish sentiment in the short to medium term....

Read More

Is Avalo Therapeutics, Inc. overvalued or undervalued?

As of 8 July 2024, Avalo Therapeutics, Inc. has moved from a risky valuation grade to one that does not qualify. Given the current metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 0.36, an EV to EBIT of 1.55, and an EV to EBITDA of 1.56, which suggest that the company is not generating sufficient value relative to its market price. In comparison to peers, Avalo's valuation ratios are significantly lower, with 180 Life Sciences Corp. showing an EV to EBITDA of -61.84 and ABVC BioPharma, Inc. at -23.18, indicating that Avalo is not alone in facing valuation challenges within its sector. Despite recent stock performance showing a 59.89% year-to-date return compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a staggering -99.85% return over the past five years....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-50.05%
EBIT Growth (5y)
-162.51%
EBIT to Interest (avg)
-31.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.33
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.57%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.36
EV to EBIT
1.55
EV to EBITDA
1.56
EV to Capital Employed
-78.19
EV to Sales
-78.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-37.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (2.76%)

Foreign Institutions

Held by 9 Foreign Institutions (1.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -58.78% vs 62.89% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.20",
          "val2": "-14.50",
          "chgp": "-32.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.50",
          "val2": "0.40",
          "chgp": "-725.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.80",
          "val2": "-13.10",
          "chgp": "-58.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -78.95% vs -89.50% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.43% vs 24.46% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "1.90",
          "chgp": "-78.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-40.70",
          "val2": "-23.30",
          "chgp": "-74.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "3.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.50",
          "val2": "-4.60",
          "chgp": "154.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.10",
          "val2": "-31.50",
          "chgp": "-11.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-92,678.00%",
          "val2": "-12,185.00%",
          "chgp": "-8,049.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.20
-14.50
-32.41%
Interest
0.00
0.00
Exceptional Items
-2.50
0.40
-725.00%
Consolidate Net Profit
-20.80
-13.10
-58.78%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -58.78% vs 62.89% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.40
1.90
-78.95%
Operating Profit (PBDIT) excl Other Income
-40.70
-23.30
-74.68%
Interest
0.00
3.40
-100.00%
Exceptional Items
2.50
-4.60
154.35%
Consolidate Net Profit
-35.10
-31.50
-11.43%
Operating Profit Margin (Excl OI)
-92,678.00%
-12,185.00%
-8,049.30%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -78.95% vs -89.50% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.43% vs 24.46% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Avalo Therapeutics, Inc. stock-summary
stock-summary
Avalo Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
Company Coordinates stock-summary
Company Details
540 Gaither Rd Ste 400 , ROCKVILLE MD : 20850-6713
stock-summary
Tel: 1 410 5228707
stock-summary
http://www.cerecor.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."